Last reviewed 2026-04-20 · How we verify

Remifentanil R8

Helse Fonna · FDA-approved active Small molecule Quality 2/100

Remifentanil R8 is a Small molecule drug developed by Helse Fonna. It is currently FDA-approved. Also known as: Ultiva.

At a glance

Generic name	Remifentanil R8
Also known as	Ultiva
Sponsor	Helse Fonna
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Hemodynamics During Induction of General Anesthesia With Medium or Low Remifentanil Doses. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Remifentanil R8 CI brief — competitive landscape report
Remifentanil R8 updates RSS · CI watch RSS
Helse Fonna portfolio CI

Frequently asked questions about Remifentanil R8

What is Remifentanil R8?

Remifentanil R8 is a Small molecule drug developed by Helse Fonna.

Who makes Remifentanil R8?

Remifentanil R8 is developed and marketed by Helse Fonna (see full Helse Fonna pipeline at /company/helse-fonna).

Is Remifentanil R8 also known as anything else?

Remifentanil R8 is also known as Ultiva.

What development phase is Remifentanil R8 in?

Remifentanil R8 is FDA-approved (marketed).

Manufacturer: Helse Fonna — full pipeline
Also known as: Ultiva
Compare: Remifentanil R8 vs similar drugs
Pricing: Remifentanil R8 cost, discount & access